A combinatorial approach toward the generation of ambiphilic peptide-based inhibitors of protein:geranylgeranyl transferase-1

Journal of Combinatorial Chemistry

Volumn 7, Issue 5, 2005, Pages 703-713

  Oualid, Farid El ^a   Van Den Elst, Hans ^a   Leroy, Ingrid M ^b   Pieterman, Elsbeth ^b   Cohen, Louis H ^b   Burm, Brigitte E A ^a   Overkleeft, Herman S ^a   Van Der Marel, Gijs A ^a   Overhand, Mark ^a  

^a LEIDEN UNIVERSITY   (Netherlands)

^b TNO   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

GERANYLGERANYLTRANSFERASE TYPE I; GERANYLGERANYLTRANSFERASE TYPE-I; OLIGOPEPTIDE; TRANSFERASE;

ANIMAL; ARTICLE; CATTLE; CHEMISTRY; COMBINATORIAL CHEMISTRY; DRUG ANTAGONISM; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; METHODOLOGY; STRUCTURE ACTIVITY RELATION; SYNTHESIS;

ALKYL AND ARYL TRANSFERASES; ANIMALS; CATTLE; CHROMATOGRAPHY, LIQUID; COMBINATORIAL CHEMISTRY TECHNIQUES; MASS SPECTROMETRY; OLIGOPEPTIDES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 27744561834     PISSN: 15204766     EISSN: None     Source Type: Journal    
DOI: 10.1021/cc0500203     Document Type: Article

References (67)

1. (a) Roskoski Jr, R. Biochem. Biophys. Res. Commun. 2003, 303, 1-7,
2. (b) Hao, D.; Rowinsky, E. K. Cancer Invest. 2002, 20, 387-404.
3. (c) Tamanoi, F.; Sigman, D. S. Editors of the Enzymes, 3rd ed.; Academic Press: San Diego, CA 2001; Vol 21.
4. Hinterding, K.; Alonso-Díaz, D.; Waldmann, H. Angew. Chem., Int. Ed. 1998, 37, 688-749.
5. Donovan, S.; Shannon, K. M.; Bollag, G. Biochim. Biophys. Acta 2002, 1602, 23-45.
6. For recent reviews covering the development of PFT and PGGT inhibitors, see; (a) Dinsmore, C. J.; Bell, I. M. Curr. Top. Med. Chem. 2003, 3, 1075-1093.
7. (b) Ohkanda, J.; Knowles, D. B.; Blaskovich, M. A.; Sebti, S. M.; Hamilton, A. D. Curr. Top. Med. Chem. 2002, 2, 303-323.
8. (c) Ayral-Kaloustian, S.; Salaski, E. J. Curr. Med. Chem. 2002, 9, 1003-1032.
9. (d) Gibbs, R. A.; Zahn, T. J.; Sebolt-Leopold, J. S. Curr. Med. Chem. 2001, 8, 1437-1465.
10. Park, H.-W.; Boduluri, S. R.; Moomaw, J. F.; Casey, P. J.; Beese, L. S. Science 1997, 275, 1800-1804.
11. (a) Mazieres, J.; Pradines, A.; Favre, G. Cancer Lett. 2004, 206, 159-167.
12. (b) Russo, P.; Loprevite, M.; Cesario, A.; Ardizzoni, A. Curr. Med. Chem.- Anti-Cancer Agents 2004, 4, 123-138.
13. (c) The potent and selective PFT inhibitor R115777 (Tipifarnib, Zarnestra) has been submitted to the U.S. Food and Drug Administration (FDA) for approval for the treatment of acute myeloid leukemia. See: http://www.drugs. com/nda/tipifarnib_050124.html.
14. (d) End, D. W.; Smets, G.; Todd, A. V.; Applegate, T. L.; Fuery, C. J.; Angibaud, P.; Venet, M.; Sanz, G.; Poignet, H.; Skrzat, S.; Devine, A.; Wouters, W.; Bowden, C. Cancer Res. 2001, 61, 131-137.
15. (e) Reid, T. S.; Beese, L. S. Biochemistry 2004, 43, 6877-6884.
16. Taylor, J. S.; Reid, T. S.; Terry, K. L.; Casey, P. J.; Beese, L. S. EMBO J. 2003, 22, 5963-5974.
17. (a) Marson, C. M.; Rioja, A. S.; Brooke, G.; Coombes, R. C.; Vigushin, D. M. Bioorg. Med. Chem. Lett. 2002, 12, 255-259.
18. (b) Lerner, E. C.; Qian, Y.; Hamilton, A. D.; Sebti, S. M. J. Biol. Chem. 1995, 270, 26770-26773.
19. (c) McGuire, T. F.; Qian, Y.; Vogt, A.; Hamilton, A. D.; Sebti, S. M. J. Biol. Chem. 1996, 271, 27402-27407.
20. (d) James, G. L.; Goldstein, J. L.; Brown, M. S. J. Biol. Chem. 1995, 270, 6221-6226.
21. (e) Sun, J.; Qian, Y.; Hamilton, A. D.; Sebti, S. M. Oncogene 1998, 16, 1467-1473.
22. (f) Lerner, E. C.; Zhang, T.-T.; Knowles, D. B.; Qian, Y.; Hamilton, A. D.; Sebti, S. M. Oncogene 1997, 15, 1283-1288.
23. (g) Rowell, C. A.; Kowalczyk, J. J.; Lewis, M. D.; Garcia, A. M. J. Biol. Chem. 1997, 272, 14093-14097.
24. (h) Whyte, D. B.; Kirschmeier, P.; Hockenberry, T. N.; Nunez-Oliva, I.; James, L.; Catino, J. J.; Bishop, W. R.; Pai, J.-K. J. Biol. Chem. 1997, 272, 14459-14464.
25. (a) Morgan, M. A.; Wegner, J.; Aydilek, E.; Ganser, A.; Reuter, C. W. M. Leukemia 2003, 17, 1508-1520.
26. (b) Lobell, R. B.; Omer, C. A.; Abrams, M. T.; Bhimnathwala, H. G.; Brucker, M. J.; Buser, C. A.; Davide, J. P.; deSolms, S. J.; Dinsmore, C. J.; Ellis-Hutchings, M. S.; Kral, A. M.; Liu, D.; Lumma, W. C.; Machotka, S. V.; Rands, E.; Williams, T. M.; Graham, S. L.; Hartman, G. D.; Oliff, A. I.; Heimbrook, D. C.; Kohl, N. E. Cancer Res. 2001, 61, 8758-8768.
27. (a) Finder, J. D.; Litz, J. L.; Blaskovich, M. A.; McGuire, T. F.; Qian, Y.; Hamilton, A. D.; Davies, P.; Sebti, S. M. J. Biol. Chem. 1997, 272, 13484-13488.
28. (b) Walters, C. E.; Pryce, G.; Hankey, D. J. R.; Sebti, S. M.; Hamilton, A. D.; Baker, D.; Greenwood, J.; Adamson, P. J. Immunol. 2002, 168, 4087-4094.
29. (c) Chakrabarti, D.; Azam, T.; DelVecchio, C.; Qiu, L. B.; Park, Y.; Allen, C. M. Mol. Biochem. Parasitol. 1998, 94, 175-184.
30. (d) Chakrabarti, D.; Da Silva, T.; Barger, J.; Paquette, S.; Patel, H.; Patterson, S.; Allen, C. M. J. Biol. Chem. 2002, 277, 42066-42073.
31. (e) van Beek, E.; Löwik, C. W. G. M.; van der Pluijm, G.; Papapoulos, S. J. Bone Miner. Res. 1999, 14, 722-729.
32. (f) Fisher, J. E.; Rogers, M. J.; Halasy, J. M.; Luckman, S. P.; Hughes, D. E.; Masarachia, P. J.; Wesolowski, G.; Russell, R. G.; Rodan, G. A.; Reszka, A. A. Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 133-138.
33. (g) Cohen, L. H.; Pieterman, E.; van Leeuwen, R. E. W.; Negre-Aminou, P.; Valentijn, A. R. P. M.; Overhand, M.; van der Marel, G. A.; van Boom, J. H. Biochem. Pharmacol. 1999, 57, 365-373.
34. (h) Cohen, L. H.; Pieterman, E.; van Leeuwen, R. E. W.; Burm, B. E. A.; van der Marel, G. A.; van Boom, J. H. Biochem. Pharmacol. 2000, 60, 1061-1068.
35. (i) Ye, J.; Wang, C.; Sumpter, R., Jr.; Brown, M. S.; Goldstein, J. L.; Gale, M., Jr. Proc. Natl. Acad. Sci. U.S.A. 2003, 100, 15865-15870.
36. (a) El Oualid, F.; Bruining, L.; Leroy, I. M.; Cohen, L. H.; van Boom, J. H.; van der Marel, G. A.; Overkleeft, H. S.; Overhand, M. Helv. Chim. Acta 2002, 85, 3455-3472.
37. (b) El Oualid, F.; Burm, B. E. A.; Leroy, I. M.; Cohen, L. H.; van Boom, J. H.; van den Elst, H.; Overkleeft, H. S.; van der Marel, G. A.; Overhand, M. J. Med. Chem. 2004, 47, 3920-3923.
38. (c) El Oualid, F.; Baktawar, J.; Leroy, I. M.; van den Elst, H.; Cohen, L. H.; van der Marel, G. A.; Overkleeft, H. S.; Overhand, M. Bioorg. Med. Chem. 2005, 13, 1463-1475 and references cited herein.
39. (a) Wallace, A.; Koblan, K. S.; Hamilton, K.; Marquis-Omer, D. J.; Miller, P. J.; Mosser, S. D.; Omer, C. A.; Schaber, M. D.; Cortese, R.; Oliff, A.; Jackson, J. B.; Pessi, A. J. Biol. Chem. 1996, 271, 31306-31311.
40. (b) Bogusky, M. J.; Culberson, J. C.; Pitzenberger, S. M.; Garsky, V. M.; Wallace, A.; Pessi, A.; Koblan, K. S. J. Pept. Res. 1999, 54, 66-73.
41. (c) Scholten, J. D.; Zimmerman, K.; Oxender, M.; Sebolt-Leopold, J. S.; Gowan, R.; Leonard, D.; Hupe D. J. Bioorg. Med. Chem. 1996, 4, 1537-1543.
42. (d) Leonard, D.; Schuler, K. R.; Poulter, C. J.; Eaton, S. R.; Sawyer, T. K.; Hodges, J. C.; Su, T.-Z.; Scholten, J. D.; Gowan, R. C.; Sebolt-Leopold, J. S.; Doherty, A. M. J. Med. Chem. 1997, 40, 192-200.
43. Park, J. G.; Langenwalter, K. J.; Weinbaum, C. A.; Casey, P. J.; Pang, Y.-P. J. Comb. Chem. 2004, 6, 407-314.
44. (a) Kamphausen, S.; Höltge, N.; Wirsching, F.; Morys-Wortmann, C.; Riester, D.; Goetz, R.; Thürk, M.; Schwienhorst, A. J. Comput.-Aided Mol. Des. 2002, 16, 551-567.
45. (b) Gobbi, A.; Poppinger, D. Biotechnol. Bioeng. 1998, 61, 47-54.
46. (c) Weber, L.; Wallbaum, S.; Broger, C.; Gubernator, K. Angew. Chem., Int. Ed. Engl. 1995, 34, 2280-2282.
47. (d) Singh, J.; Ator, M. A.; Jaeger, E. P.; Allen, M. P.; Whipple, D. A.; Soloweij, J. E.; Chowdhary, S.; Treasurywala, A. M. J. Am. Chem. Soc. 1996, 118, 1669-1676.
48. (e) Sheridan, R. P.; Kearsley, S. K. J. Chem. Inf. Comput. Sci. 1995, 35, 310-320.
49. (f) Weber, L. Curr. Opin. Chem. Biol. 1998, 2, 381-385.
50. (g) Hoh, C.; Dudziak, G.; Liese, A. Bioorg. Med. Chem. Lett. 2002, 12, 1031-1034.
51. (h) Bräuer, S.; Almstetter, M.; Antuch, W.; Behnke, D.; Taube, R.; Furer, P.; Hess, S. J. Comb. Chem. 2005, 7, 218-226.
52. (i) Tilgen, K.; Enderle, T.; Broger, C.; Weber, L. Chem. Biol. 2000, 7, 433-441.
53. (j) Teixidó, M.; Belda, I.; Zurita, E.; Llorà, X.; Fabre, M.; Vilaró, S.; Albericio, F.; Giralt, E. J. Pept. Sci. 2005, in press (DOI: 10.1002/psc679).
54. (k) Chen, G.; Zheng, S.; Luo, X.; Shen, J.; Zhu, W.; Liu, H.; Gui, C.; Zhang, J.; Zheng, M.; Puah, C. M.; Chen, K.; Jiang, H. J. Comb. Chem. 2005, 7, 398-406.
55. (a) Lee, H. Y.; Sohn, J.-H.; Kwon, B.-M. Bioorg. Med. Chem. Lett. 2002, 12, 1599-1602.
56. (b) Patel, D. V.; Patel, M. M.; Robinson, S. S.; Gordon, E. M. Bioorg. Med. Chem. Lett. 1994, 4, 1883-1888.
57. (c) Kotharé, M. A.; Ohkanda, J.; Lockman, J. W.; Qian, Y.; Blaskovich, M. A.; Sebti, S. M.; Hamilton, A. D. Tetrahedron 2000, 56, 9833-9841.
58. It is interesting to note that these types of compounds (i.e., A03B02C14D16 and A03B10C14D16) have been reported before and that they were found to act as bisubstrate inhibitors of PFT, in which the lipid part functions as an isoprenyl mimic. See: (a) Schlitzer, M.; Sattler, I. Angew. Chem., Int. Ed. Engl. 1999, 38, 2032-2034.
59. (b) Schlitzer, M.; Böhm, M.; Sattler, I. Bioorg. Med. Chem. 2000, 6, 2399-2406.
60. (c) Mitsch, A.; Bergemann, S.; Gust, R.; Sattler, I.; Schlitzer, M. Arch. Pharm. Med. Chem. 2003, 396, 242-250. We have recently reported (ref 11c) on the design of potential bisubstrate inhibitors of PGGT-1 with the same rationale presented in refs 16a-c. In addition, the oligopeptidic and naturally occurring PFT inhibitor Pepticinnamin E is known to act as a bisubstrate inhibitor.
61. See: (d) Hinterding, K.; Hagenbuch, P.; Rétey, J.; Waldmann, H. Angew. Chem., Int. Ed. Engl. 1998, 37, 1236-1239.
62. The yields of compounds containing building block D15 were found to be very low in some cases. LC/MS analysis indicated that a major side-product was formed during the Fmoc deprotection step with 20% piperidine in DMF. The m/z ratio of this side-product suggests that the monobenzyl-protected phosphate group has been displaced by a piperidine moeity. See: (a) Pérez, M.; Pleixats, R. Tetrahedron 1995, 51, 8355-8362.
63. (b) Wakamiya, T.; Saruta, K.; Yasuoka, J.; Kusumoto, S. Chem. Lett. 1994, 1099-1102. Although no attempts were undertaken to optimize the yield, there are two potential solutions for this problem. First, the duration of the deprotection step with piperidine can be shortened. Second, the nonnucleophilic base DBU (1,8-diazabicyclo-[5.4.0]undec-7-ene) can be employed instead of piperidine.
64. See: (c) Wade, J. D.; Bedford, J.; Sheppard, R. C.; Tregear, G. W. Pept. Res. 1991, 4, 194-199.
65. (d) Kates, S. A.; Solé, N. A.; Beyermann, M.; Barany, G.; Albericio, F. Pept. Res. 1996, 9, 106-113.
66. This assay protocol is a minor modification of the assay protocol described in ref 10g.
67. Yokoyama, K.; Goodwin, G. W.; Ghomashchi, F.; Glomset, J. A.; Gelb, M. H. Proc. Natl. Acad. Sci. U.S.A. 1991, 88, 5302-5306.